Novel Insights into the Roles of Rho Kinase in Cancer

Abe H, Kamai T, Tsujii T et al (2008) Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res 29:155–161 Abe H, Kamai T, Hayashi K et al (2014) The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells. BMC Cancer 14:412 Adachi S, Yasuda I, Nakashima M et al (2011) Rho-kinase inhibitor upregulates migration by altering focal adhesion formation via the Akt pathway in colon cancer cells. Eur J Pharmacol 650:145–150 Alhopuro P, Sammalkorpi H, Niittymaki I et al (2012) Candidate driver genes in microsatellite-unstable colorectal cancer. Int J Cancer 130:1558–1566 Amano M, Ito M, Kimura K et al (1996) Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271:20246–20249 Amano M, Chihara K, Nakamura N et al (1999) The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity. J Biol Chem 274:32418–32424 Amano T, Tanabe K, Eto T et al (2001) LIM-kinase 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinase-catalysed phosphorylation at threonine-505. Biochem J 354(Pt 1):149–159 Amano M, Nakayama M, Kaibuchi K (2010a) Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton 67:545–554 Amano M, Tsumura Y, Taki K et al (2010b) A proteomic approach for comprehensively screening substrates of protein kinases such as Rho-kinase. PLoS One 5:e8704 An L, Liu Y, Wu A et al (2013) microRNA-124 inhibits migration and invasion by down-regulating ROCK1 in glioma. PLoS One 8:e69478 Asano T, Ikegaki I, Satoh S et al (1987) Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 241:1033–1040 Babelova A, Jansen F, Sander K et al (2013) Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease. PLoS One 8:e80328 Bacharach J, Dubiner HB, Levy B et al (2015) Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology 122:302–307 Bain J, Plater L, Elliott M et al (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297–315 Blumenstein L, Ahmadian MR (2004) Models of the cooperative mechanism for Rho effector recognition: implications for RhoA-mediated effector activation. J Biol Chem 279:53419–53426 Boerma M, Fu Q, Wang J et al (2008) Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 19:709–718 Breitenlechner C, Gassel M, Hidaka H et al (2003) Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 11:1595–1607 Brew CT, Aronchik I, Kosco K et al (2009) Indole-3-carbinol inhibits MDA-MB-231 breast cancer cell motility and induces stress fibers and focal adhesion formation by activation of Rho kinase activity. Int J Cancer 124:2294–2302 Burthem J, Rees-Unwin K, Mottram R et al (2007) The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells. Leukemia 21:1708–1714 Cai H, Lin L, Tang M et al (2014) Combined microRNA-340 and ROCK1 mRNA profiling predicts tumor progression and prognosis in pediatric osteosarcoma. Int J Mol Sci 15:560–573 Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866 Cao XX, Xu JD, Xu JW et al (2011) RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway. Breast Cancer Res Treat 126:555–563 Castro DJ, Maurer J, Hebbard L et al (2013) ROCK1 inhibition promotes the self-renewal of a novel mouse mammary cancer stem cell. Stem Cells 31:12–22 Chen W, Mao K, Liu Z et al (2014) The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (review). Oncol Lett 8:1907–1911 Choi DS, Stark DJ, Raphael RM et al (2015) SDF-1alpha stiffens myeloma bone marrow mesenchymal stromal cells through the activation of RhoA-ROCK-Myosin II. Int J Cancer 136:E219–E229 Chong CM, Shen M, Zhou ZY et al (2014) Discovery of a benzofuran derivative (MBPTA) as a novel ROCK inhibitor in protecting against MPP-induced oxidative stress and cell death in SH-SY5Y cells. Free Radic Biol Med 74:283–293 Chuang HH, Yang CH, Tsay YG et al (2012) ROCKII Ser1366 phosphorylation reflects the activation status. Biochem J 443:145–151 Chun KH, Araki K, Jee Y et al (2012) Regulation of glucose transport by ROCK1 differs from that of ROCK2 and is controlled by actin polymerization. Endocrinology 153:1649–1662 Cimino D, De Pitta C, Orso F et al (2013) miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J 27:1223–1235 Coleman ML, Sahai EA, Yeo M et al (2001) Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 3:339–345 Couzens AL, Saridakis V, Scheid MP (2009) The hydrophobic motif of ROCK2 requires association with the N-terminal extension for kinase activity. Biochem J 419:141–148 Couzens AL, Gill RM, Scheid MP (2014) Characterization of a modified ROCK2 protein that allows use of N6-ATP analogs for the identification of novel substrates. BMC Biotechnol 14:2 Cui G, Cui M, Li Y et al (2014) MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells. Tumour Biol 35:8933–8937 Dachsel JC, Ngok SP, Lewis-Tuffin LJ et al (2013) The Rho guanine nucleotide exchange factor Syx regulates the balance of dia and ROCK activities to promote polarized-cancer-cell migration. Mol Cell Biol 33:4909–4918 Davies SP, Reddy H, Caivano M et al (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351(Pt 1):95–105 de Toledo M, Anguille C, Roger L et al (2012) Cooperative anti-invasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activity. PLoS One 7:e48344 Di Savino A, Panuzzo C, Rocca S et al (2015) Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood 125:2245–2253 Doran JD, Liu X, Taslimi P et al (2004) New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications. Biochem J 384(Pt 2):255–262 Du J, Hannon GJ (2004) Suppression of p160ROCK bypasses cell cycle arrest after Aurora-A/STK15 depletion. Proc Natl Acad Sci USA 101:8975–8980 Dvorsky R, Blumenstein L, Vetter IR et al (2004) Structural insights into the interaction of ROCKI with the switch regions of RhoA. J Biol Chem 279:7098–7104 Feng Y, LoGrasso PV (2014) Rho kinase inhibitors: a patent review (2012–2013). Expert Opin Ther Pat 24:295–307 Feng J, Ito M, Kureishi Y et al (1999) Rho-associated kinase of chicken gizzard smooth muscle. J Biol Chem 274:3744–3752 Feng Y, Yin Y, Weiser A et al (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J Med Chem 51:6642–6645 Ferretti R, Palumbo V, Di Savino A et al (2010) Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis. Dev Cell 18:486–495 Fife CM, McCarroll JA, Kavallaris M (2014) Movers and shakers: cell cytoskeleton in cancer metastasis. Br J Pharmacol 171:5507–5523 Fu X, Gong MC, Jia T et al (1998) The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPgammaS-, and phorbol ester-induced Ca2+-sensitization of smooth muscle. FEBS Lett 440:183–187 Fujisawa K, Fujita A, Ishizaki T et al (1996) Identification of the Rho-binding domain of p160ROCK, a Rho-associated coiled-coil containing protein kinase. J Biol Chem 271:23022–23028 Fukata Y, Oshiro N, Kinoshita N et al (1999) Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. J Cell Biol 145:347–361 Fukumoto Y, Shimokawa H (2013) Rho-kinase inhibitors. Handb Exp Pharmacol 218:351–363 Fusella F, Ferretti R, Recupero D et al (2014) Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway. J Pathol 234:152–163 Garg R, Riento K, Keep N et al (2008) N-terminus-mediated dimerization of ROCK-I is required for RhoE binding and actin reorganization. Biochem J 411:407–414 Garnock-Jones KP (2014) Ripasudil: first global approval. Drugs 74:2211–2215 Gilkes DM, Xiang L, Lee SJ et al (2014) Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci USA 111:E384–E393 Gong LL, Fang LH, Peng JH et al (2010) Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors. J Biotechnol 145:295–303 Gong L, Peng J, Fang L et al (2012) The vasorelaxant mechanisms of a Rho kinase inhibitor DL0805 in rat thoracic aorta. Molecules 17:5935–5944 Grisk O, Schluter T, Reimer N et al (2012) The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens 30:980–989 Guagnini F, Ferazzini M, Grasso M et al (2012) Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. J Transl Med 10:59 Guan R, Xu X, Chen M et al (2013) Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. Eur J Med Chem 70:613–622 He M, Cheng Y, Li W et al (2010) Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer 10:170 Herskowitz JH, Feng Y, Mattheyses AL et al (2013) Pharmacologic inhibition of ROCK2 suppresses amyloid-beta production in an Alzheimer’s disease mouse model. J Neurosci 33:19086–19098 Hu CB, Li QL, Hu JF et al (2014) miR-124 inhibits growth and invasion of gastric cancer by targeting ROCK1. Asian Pac J Cancer Prev 15:6543–6546 Huang H, Lee DH, Zabolotny JM et al (2013) Metabolic actions of Rho-kinase in periphery and brain. Trends Endocrinol Metab 24:506–514 Inaba N, Ishizawa S, Kimura M et al (2010) Effect of inhibition of the ROCK isoform on RT2 malignant glioma cells. Anticancer Res 30:3509–3514 Ishizaki T, Maekawa M, Fujisawa K et al (1996) The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15:1885–1893 Ishizaki T, Uehata M, Tamechika I et al (2000) Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 57:976–983 Isobe T, Mizuno K, Kaneko Y et al (2014) Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res 39:813–822 Itoh K, Yoshioka K, Akedo H et al (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5:221–225 Jacobs M, Hayakawa K, Swenson L et al (2006) The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem 281:260–268 Jeong KJ, Park SY, Cho KH et al (2012) The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 31:4279–4289 Jiang L, Liu X, Kolokythas A et al (2010) Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 127:505–512 Julian L, Olson MF (2014) Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases 5:e29846 Kale VP, Hengst JA, Desai DH et al (2014) A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasion. Cancer Lett 354:299–310 Kale VP, Hengst JA, Desai DH et al (2015) The regulatory roles of ROCK and MRCK kinases in the plasticity of cancer cell migration. Cancer Lett 361:185–196 Kalender ME, Demiryurek S, Oztuzcu S et al (2010) Association between the Thr431Asn polymorphism of the ROCK2 gene and risk of developing metastases of breast cancer. Oncol Res 18:583–591 Kang JH, Asai D, Tsuchiya A et al (2011) Peptide substrates for Rho-associated kinase 2 (Rho-kinase 2/ROCK2). PLoS One 6:e22699 Kawano Y, Fukata Y, Oshiro N et al (1999) Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 147:1023–1038 Kiel JW, Kopczynski CC (2015) Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits. J Ocul Pharmacol Ther 31:146–151 Kimura K, Ito M, Amano M et al (1996) Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273:245–248 Knipe RS, Tager AM, Liao JK (2015) The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev 67:103–117 Knowles LM, Gurski LA, Maranchie JK et al (2015) Fibronectin matrix formation is a prerequisite for colonization of kidney tumor cells in fibrin. J Cancer 6:98–104 Komander D, Garg R, Wan PT et al (2008) Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure. EMBO J 27:3175–3185 Kopczynski C, Novack GD, Swearingen D et al (2013) Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers. Br J Ophthalmol 97:567–572 Kroiss A, Vincent S, Decaussin-Petrucci M et al (2015) Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene 34:2846–2855 Kureishi Y, Kobayashi S, Amano M et al (1997) Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem 272:12257–12260 Lane J, Martin TA, Watkins G et al (2008) The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 33:585–593 Lasker GF, Pankey EA, Allain AV et al (2013) The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat. Urology 81:465 e467–465 e414 Lee HH, Tien SC, Jou TS et al (2010) Src-dependent phosphorylation of ROCK participates in regulation of focal adhesion dynamics. J Cell Sci 123(Pt 19):3368–3377 Lee JH, Zheng Y, von Bornstadt D et al (2014a) Selective ROCK2 Inhibition in focal cerebral ischemia. Ann Clin Transl Neurol 1:2–14 Lee SH, Huang H, Choi K et al (2014b) ROCK1 isoform-specific deletion reveals a role for diet-induced insulin resistance. Am J Physiol Endocrinol Metab 306:E332–E343 Leung T, Chen XQ, Manser E et al (1996) The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 16:5313–5327 Levy B, Ramirez N, Novack GD et al (2015) Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol 159(980–985):e981 Li Z, Chang Z, Chiao LJ et al (2009) TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res 69:7851–7859 Li R, Martin MP, Liu Y et al (2012) Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. J Med Chem 55:2474–2478 Li F, Jiang Q, Shi KJ et al (2013a) RhoA modulates functional and physical interaction between ROCK1 and Erk1/2 in selenite-induced apoptosis of leukaemia cells. Cell Death Dis 4:e708 Li J, Song Y, Wang Y et al (2013b) MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem 380:277–282 Li N, Tang A, Huang S et al (2013c) MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway. Mol Cell Biochem 380:107–119 Li E, Zhang J, Yuan T et al (2014a) miR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1. Tumour Biol 35:7645–7650 Li G, Liu L, Shan C et al (2014b) RhoA/ROCK/PTEN signaling is involved in AT-101-mediated apoptosis in human leukemia cells in vitro and in vivo. Cell Death Dis 5:e998 Li YH, Yu JZ, Liu CY et al (2014c) Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis. Immunology 143:219–229 Li H, Jiang X, Yu Y et al (2015a) KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway. Oncogene 34:1432–1441 Li J, Bharadwaj SS, Guzman G et al (2015b) ROCK I has more accurate prognostic value than MET in predicting patient survival in colorectal cancer. Anticancer Res 35:3267–3273 Lin T, Zeng L, Liu Y et al (2003) Rho-ROCK-LIMK-cofilin pathway regulates shear stress activation of sterol regulatory element binding proteins. Circ Res 92:1296–1304 Lin SL, Chiang A, Chang D et al (2008) Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14:417–424 Liu S, Goldstein RH, Scepansky EM et al (2009) Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 69:8742–8751 Liu P, Morrison C, Wang L et al (2012a) Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 33:1270–1276 Liu X, Ory V, Chapman S et al (2012b) ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 180:599–607 Liu L, Li G, Li Q et al (2013) Triptolide induces apoptosis in human leukemia cells through caspase-3-mediated ROCK1 activation and MLC phosphorylation. Cell Death Dis 4:e941 Lochhead PA, Wickman G, Mezna M et al (2010) Activating ROCK1 somatic mutations in human cancer. Oncogene 29:2591–2598 Lock FE, Ryan KR, Poulter NS et al (2012) Differential regulation of adhesion complex turnover by ROCK1 and ROCK2. PLoS One 7:e31423 Lohn M, Plettenburg O, Ivashchenko Y et al (2009) Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 54:676–683 Lowery DM, Clauser KR, Hjerrild M et al (2007) Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 26:2262–2273 Lynch J, Fay J, Meehan M et al (2012) MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis 33:976–985 Ma W, Wong CC, Tung EK et al (2013) RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway. Hepatology 57:152–161 Maekawa M, Ishizaki T, Boku S et al (1999) Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 285:895–898 Majid S, Dar AA, Saini S et al (2012) MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One 7:e46743 Mali RS, Ramdas B, Ma P et al (2011) Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell 20:357–369 Mali RS, Kapur S, Kapur R (2014) Role of Rho kinases in abnormal and normal hematopoiesis. Curr Opin Hematol 21:271–275 Mardilovich K, Olson MF, Baugh M (2012) Targeting Rho GTPase signaling for cancer therapy. Future Oncol 8:165–177 Matsui T, Amano M, Yamamoto T et al (1996) Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 15:2208–2216 Matsui T, Maeda M, Doi Y et al (1998) Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 140:647–657 Matsuoka T, Yashiro M (2014) Rho/ROCK signaling in motility and metastasis of gastric cancer. World J Gastroenterol 20:13756–13766 Matsuoka T, Yashiro M, Kato Y et al (2011) RhoA/ROCK signaling mediates plasticity of scirrhous gastric carcinoma motility. Clin Exp Metastasis 28:627–636 Mertsch S, Thanos S (2014) Opposing signaling of ROCK1 and ROCK2 determines the switching of substrate specificity and the mode of migration of glioblastoma cells. Mol Neurobiol 49:900–915 Mikuriya Y, Tashiro H, Kuroda S et al (2015) Fatty liver creates a pro-metastatic microenvironment for hepatocellular carcinoma through activation of hepatic stellate cells. Int J Cancer 136:E3–E13 Mishra RK, Alokam R, Singhal SM et al (2014) Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation. J Chem Inf Model 54:2876–2886 Montalvo J, Spencer C, Hackathorn A et al (2013) ROCK1 and 2 perform overlapping and unique roles in angiogenesis and angiosarcoma tumor progression. Curr Mol Med 13:205–219 Morgan-Fisher M, Wewer UM, Yoneda A (2013) Regulation of ROCK activity in cancer. J Histochem Cytochem 61:185–198 Nakabayashi H, Shimizu K (2011) HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways. Cancer Sci 102:393–399 Nakagawa O, Fujisawa K, Ishizaki T et al (1996) ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 392:189–193 Nakashima M, Adachi S, Yasuda I et al (2010) Rho-kinase regulates negatively the epidermal growth factor-stimulated colon cancer cell proliferation. Int J Oncol 36:585–592 Nakashima M, Adachi S, Yasuda I et al (2011) Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells. Mol Cancer 10:79 Newell-Litwa KA, Badoual M, Asmussen H et al (2015) ROCK1 and 2 differentially regulate actomyosin organization to drive cell and synaptic polarity. J Cell Biol 210:225–242 Nishioka T, Shohag MH, Amano M, Kaibuchi K (2015) Developing novel methods to search for substrates of protein kinases such as Rho-kinase. Biochim Biophys Acta 1854(10 Pt B):1663–1666 Nishioka T, Nakayama M, Amano M et al (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3zeta affinity chromatography. Cell Struct Funct 37:39–48 Ogata S, Morishige K, Sawada K et al (2009) Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells. Int J Gynecol Cancer 19:1473–1480 Oh KS, Mun J, Cho JE et al (2013a) Discovery of novel scaffolds for Rho kinase 2 inhibitor through TRFRET-based high throughput screening assay. Comb Chem High Throughput Screen 16:37–46 Oh KS, Oh BK, Park CH et al (2013b) Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865). Eur J Pharmacol 702:218–226 Ohashi K, Nagata K, Maekawa M et al (2000) Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem 275:3577–3582 Ohata H, Ishiguro T, Aihara Y et al (2012) Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells. Cancer Res 72:5101–5110 Ohta T, Takahashi T, Shibuya T et al (2012) Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1alpha in human ovarian cancer cells. Cancer Biol Ther 13:25–33 Oku Y, Tareyanagi C, Takaya S et al (2014) Multimodal effects of small molecule ROCK and LIMK inhibitors on mitosis, and their implication as anti-leukemia agents. PLoS One 9:e92402 Ongusaha PP, Kim HG, Boswell SA et al (2006) RhoE is a pro-survival p53 target gene that inhibits ROCK I-mediated apoptosis in response to genotoxic stress. Curr Biol 16:2466–2472 Palechor-Ceron N, Suprynowicz FA, Upadhyay G et al (2013) Radiation induces diffusible feeder cell factor(s) that cooperate with ROCK inhibitor to conditionally reprogram and immortalize epithelial cells. Am J Pathol 183:1862–1870 Pankey EA, Byun RJ, Smith WB et al (2012) The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat. Can J Physiol Pharmacol 90:825–835 Pankova D, Jobe N, Kratochvilova M et al (2012) NG2-mediated Rho activation promotes amoeboid invasiveness of cancer cells. Eur J Cell Biol 91:969–977 Patel RA, Forinash KD, Pireddu R et al (2012) RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res 72:5025–5034 Patel RA, Liu Y, Wang B et al (2014) Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene 33:550–555 Pearce LR, Komander D, Alessi DR (2010) The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 11:9–22 Peng J, Zhang G, Wang Q et al (2012) ROCK cooperated with ET-1 to induce epithelial to mesenchymal transition through SLUG in human ovarian cancer cells. Biosci Biotechnol Biochem 76:42–47 Peng F, Jiang J, Yu Y et al (2013) Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. Br J Cancer 109:3092–3104 Pinner S, Sahai E (2008) PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 10:127–137 Pireddu R, Forinash KD, Sun NN et al (2012) Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm 3:699–709 Prudnikova TY, Rawat SJ, Chernoff J (2015) Molecular pathways: targeting the kinase effectors of RHO-family GTPases. Clin Cancer Res 21:24–29 Rana MK, Worthylake RA (2012) Novel mechanism for negatively regulating Rho-kinase (ROCK) signaling through Coronin1B protein in neuregulin 1 (NRG-1)-induced tumor cell motility. J Biol Chem 287:21836–21845 Rath N, Olson MF (2012) Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep 13:900–908 Riento K, Guasch RM, Garg R et al (2003) RhoE binds to ROCK I and inhibits downstream signaling. Mol Cell Biol 23:4219–4229 Rikitake Y, Oyama N, Wang CY et al (2005) Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1 ± haploinsufficient mice. Circulation 112:2959–2965 Rochelle T, Daubon T, Van Troys M et al (2013) p210bcr-abl induces amoeboid motility by recruiting ADF/destrin through RhoA/ROCK1. FASEB J 27:123–134 Routhier A, Astuccio M, Lahey D et al (2010) Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol Rep 23:861–867 Sadok A, Marshall CJ (2014) Rho GTPases: masters of cell migration. Small GTPases 5:e29710 Sadok A, McCarthy A, Caldwell J et al (2015) Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. Cancer Res 75:2272–2284 Saenz FR, Ory V, AlOtaiby M et al (2014) Conditionally reprogrammed normal and transformed mouse mammary epithelial cells display a progenitor-cell-like phenotype. PLoS One 9:e97666 Saito K, Ozawa Y, Hibino K et al (2012) FilGAP, a Rho/Rho-associated protein kinase-regulated GTPase-activating protein for Rac, controls tumor cell migration. Mol Biol Cell 23:4739–4750 Samuel MS, Lopez JI, McGhee EJ et al (2011) Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 19:776–791 Sapet C, Simoncini S, Loriod B et al (2006) Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood 108:1868–1876 Sari I, Berberoglu B, Ozkara E et al (2013) Role of rho-kinase gene polymorphisms and protein expressions in colorectal cancer development. Pathobiology 80:138–145 Sawada N, Liao JK (2014) Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal 20:1251–1267 Schackmann RC, van Amersfoort M, Haarhuis JH et al (2011) Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest 121:3176–3188 Schmidt LJ, Duncan K, Yadav N et al (2012) RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol 26:716–735 Schofield AV, Bernard O (2013) Rho-associated coiled-coil kinase (ROCK) signaling and disease. Crit Rev Biochem Mol Biol 48:301–316 Sebbagh M, Renvoize C, Hamelin J et al (2001) Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol 3:346–352 Sebbagh M, Hamelin J, Bertoglio J et al (2005) Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med 201:465–471 Shen M, Yu H, Li Y et al (2013) Discovery of Rho-kinase inhibitors by docking-based virtual screening. Mol Biosyst 9:1511–1521 Shi J, Wei L (2007) Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp 55:61–75 Shi J, Wei L (2013) Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol 62:341–354 Shi J, Zhang L, Wei L (2011) Rho-kinase in development and heart failure: insights from genetic models. Pediatr Cardiol 32:297–304 Shi J, Surma M, Zhang L et al (2013a) Dissecting the roles of ROCK isoforms in stress-induced cell detachment. Cell Cycle 12:1492–1500 Shi J, Wu X, Surma M et al (2013b) Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis 4:e483 Shibuya M, Suzuki Y, Sugita K et al (1992) Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 76:571–577 Shimizu Y, Thumkeo D, Keel J et al (2005) ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 168:941–953 Shimizu T, Fukumoto Y, Tanaka S et al (2013) Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Arterioscler Thromb Vasc Biol 33:2780–2791 Shin JY, Kim YI, Cho SJ et al (2014) MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer. PLoS One 9:e85205 Shirao S, Kashiwagi S, Sato M et al (2002) Sphingosylphosphorylcholine is a novel messenger for Rho-kinase-mediated Ca2+ sensitization in the bovine cerebral artery: unimportant role for protein kinase C. Circ Res 91:112–119 Soliman H, Nyamandi V, Garcia-Patino M et al (2015) Partial deletion of ROCK2 protects mice from high-fat diet-induced cardiac insulin resistance and contractile dysfunction. American journal of physiology. Am J Physiol Heart Circ Physiol 309:H70–H81 Spencer C, Montalvo J, McLaughlin SR et al (2011) Small molecule inhibition of cytoskeletal dynamics in melanoma tumors results in altered transcriptional expression patterns of key genes involved in tumor initiation and progression. Cancer Genomics Proteomics 8:77–85 Stiles JM, Kurisetty V, Mitchell DC et al (2013) Rho kinase proteins regulate global miRNA expression in endothelial cells. Cancer Genomics Proteomics 10:251–263 Street CA, Bryan BA (2011) Rho kinase proteins–pleiotropic modulators of cell survival and apoptosis. Anticancer Res 31:3645–3657 Street CA, Routhier AA, Spencer C et al (2010) Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells. Int J Oncol 37:1297–1305 Sumi T, Matsumoto K, Nakamura T (2001) Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J Biol Chem 276:670–676 Suprynowicz FA, Upadhyay G, Krawczyk E et al (2012) Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proc Natl Acad Sci USA 109:20035–20040 Surma M, Handy C, Chang J et al (2014) ROCK1 deficiency enhances protective effects of antioxidants against apoptosis and cell detachment. PLoS One 9:e90758 Takeba Y, Matsumoto N, Watanabe M et al (2012) The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells. Cancer Chemother Pharmacol 69:1545–1555 Tang F, Zou F, Peng Z et al (2011) N, N’-dinitrosopiperazine-mediated ezrin protein phosphorylation via activation of Rho kinase and protein kinase C is involved in metastasis of nasopharyngeal carcinoma 6–10B cells. J Biol Chem 286:36956–36967 Tanihara H, Inoue T, Yamamoto T et al (2013a) Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol 131:1288–1295 Tanihara H, Inoue T, Yamamoto T et al (2013b) Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 156:731–736 Thumkeo D, Keel J, Ishizaki T et al (2003) Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 23:5043–5055 Tilson SG, Haley EM, Triantafillu UL et al (2015) ROCK inhibition facilitates in vitro expansion of glioblastoma stem-like cells. PLoS One 10:e0132823 Timpson P, McGhee EJ, Morton JP et al (2011) Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Cancer Res 71:747–757 Tsai CC, Liu HF, Hsu KC et al (2011) 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration. Biochem Pharmacol 81:856–865 Uehata M, Ishizaki T, Satoh H et al (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389:990–994 Ueno K, Hirata H, Shahryari V et al (2011) Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma. Br J Cancer 104:308–315 Upadhyaya M, Spurlock G, Thomas L et al (2012) Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Hum Mutat 33:763–776 Van de Velde S, Van Bergen T et al (2014) AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci 55:1006–1016 Vega FM, Fruhwirth G, Ng T et al (2011) RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. J Cell Biol 193:655–665 Vigil D, Kim TY, Plachco A et al (2012) ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res 72:5338–5347 Vishnubhotla R, Bharadwaj S, Sun S et al (2012) Treatment with Y-27632, a ROCK inhibitor, increases the proinvasive nature of SW620 cells on 3D collagen type 1 matrix. Int J Cell Biol 2012:259142 Vogel CJ, Smit MA, Maddalo G et al (2015) Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK. Pigment Cell Melanoma Res 28:307–317 Voorneveld PW, Kodach LL, Jacobs RJ et al (2014) Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology 147:196.e113–208.e113 Wan X, Cheng Q, Peng R et al (2014) ROCK1, a novel target of miR-145, promotes glioma cell invasion. Mol Med Rep 9:1877–1882 Wang HF, Takenaka K, Nakanishi A et al (2011) BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2. Cancer Res 71:68–77 Wang J, Liu XH, Yang ZJ et al (2014) The effect of ROCK-1 activity change on the adhesive and invasive ability of Y79 retinoblastoma cells. BMC Cancer 14:89 Wang RF, Williamson JE, Kopczynski C et al (2015) Effect of 0.04 % AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma 24:51–54 Watanabe K, Ueno M, Kamiya D et al (2007) A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 25:681–686 Watzlawick R, Sena ES, Dirnagl U et al (2014) Effect and reporting bias of RhoA/ROCK-blockade intervention on locomotor recovery after spinal cord injury: a systematic review and meta-analysis. JAMA Neurol 71:91–99 Wei L, Surma M, Gough G et al (2015) Dissecting the mechanisms of doxorubicin and oxidative stress-induced cytotoxicity: the involvement of actin cytoskeleton and ROCK1. PLoS One 10:e0131763 Wen W, Liu W, Yan J et al (2008) Structure basis and unconventional lipid membrane binding properties of the PH-C1 tandem of rho kinases. J Biol Chem 283:26263–26273 Wen X, Huang A, Liu Z et al (2014) Downregulation of ROCK2 through nanocomplex sensitizes the cytotoxic effect of temozolomide in U251 glioma cells. PLoS One 9:e92050 Wermke M, Camgoz A, Paszkowski-Rogacz M et al (2015) RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug. Blood 125:3760–3768 Williams RD, Novack GD, van Haarlem T et al (2011) Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol 152(834–841):e831 Wong CC, Wong CM, Tung EK et al (2009) Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 49:1583–1594 Wong CC, Wong CM, Tung EK et al (2011) The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 140:322–331 Wong SY, Ulrich TA, Deleyrolle LP et al (2015) Constitutive activation of myosin-dependent contractility sensitizes glioma tumor-initiating cells to mechanical inputs and reduces tissue invasion. Cancer Res 75:1113–1122 Xu Z, Zheng X, Yang L et al (2015) Chemokine receptor 7 promotes tumor migration and invasiveness via the RhoA/ROCK pathway in metastatic squamous cell carcinoma of the head and neck. Oncol Rep 33:849–855 Yamaguchi H, Kasa M, Amano M et al (2006) Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. Structure 14:589–600 Yamamoto K, Maruyama K, Himori N et al (2014) The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci 55:7126–7136 Yang S, Kim HM (2012) The RhoA-ROCK-PTEN pathway as a molecular switch for anchorage dependent cell behavior. Biomaterials 33:2902–2915 Yang S, Kim HM (2014) ROCK inhibition activates MCF-7 cells. PLoS One 9:e88489 Yang X, Zhang Y, Wang S et al (2010) Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro. Can J Physiol Pharmacol 88:874–879 Yang X, Di J, Zhang Y et al (2012) The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed Pharmacother 66:221–227 Yin Z, Sun J (2014) Curcumin induces human SKOV3 cell apoptosis via the activation of Rho-kinase. Eur J Gynaecol Oncol 35:433–437 Yoneda A, Morgan-Fisher M, Wait R et al (2012) A collapsin response mediator protein 2 isoform controls myosin II-mediated cell migration and matrix assembly by trapping ROCK II. Mol Cell Biol 32:1788–1804 Yoshikawa T, Wu J, Otsuka M et al (2015) ROCK inhibition enhances microRNA function by promoting deadenylation of targeted mRNAs via increasing PAIP2 expression. Nucleic Acids Res 43:7577–7589 Yugawa T, Nishino K, Ohno S et al (2013) Noncanonical NOTCH signaling limits self-renewal of human epithelial and induced pluripotent stem cells through ROCK activation. Mol Cell Biol 33:4434–4447 Zanin-Zhorov A, Weiss JM, Nyuydzefe MS et al (2014) Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA 111:16814–16819 Zhang YM, Bo J, Taffet GE et al (2006) Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J 20:916–925 Zhang L, Valdez JM, Zhang B et al (2011) ROCK inhibitor Y-27632 suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells and increases their cloning efficiency. PLoS One 6:e18271 Zhang Z, Ren JH, Li ZY et al (2012) Fasudil inhibits lung carcinoma-conditioned endothelial cell viability and migration. Oncol Rep 27:1561–1566 Zhang C, Zhang S, Zhang Z et al (2014) ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene 33:5582–5591 Zhang P, Lu Y, Liu XY et al (2015) Knockdown of Rho-associated protein kinase 1 suppresses proliferation and invasion of glioma cells. Tumour Biol 36:421–428 Zheng B, Liang L, Wang C et al (2011) MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 17:7574–7583 Zheng F, Liao YJ, Cai MY et al (2012) The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 61:278–289 Zheng F, Liao YJ, Cai MY et al (2015) Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. PLoS Genet 11:e1004873 Zhou X, Wei M, Wang W (2013) MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1. Biochem Biophys Res Commun 437:653–658 Zhu F, Zhang Z, Wu G et al (2011) Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. Med Oncol 28:565–571